Medicus Pharma (MDCXW) Debt to Equity (2025)
Medicus Pharma (MDCXW) reported Debt to Equity of -$78.03 for Q4 2025, down 942.06% quarter-over-quarter from -$7.49 in Q3 2025.
Medicus Pharma (MDCXW) Debt to Equity (2025) Analysis & Trends
Medicus Pharma has reported Debt to Equity for 1 years, with the latest figure at -$78.03 in Q4 2025.
- For the quarter ending Q4 2025, Debt to Equity changed N/A year-over-year to -$78.03; the trailing twelve-month figure through Dec 2025 stood at -$78.03 (changed N/A YoY), and the FY2025 full-year result was -$78.03, changed N/A from the prior year.
- Debt to Equity for Q4 2025 stood at -$78.03, down from -$7.49 in the prior quarter.
- The five-year high for Debt to Equity was $1.45 in Q2 2025, with the low at -$78.03 in Q4 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Debt/Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 92,316,836.42 Bn | 92,316,831.46 Bn | 7.76 Bn | - |
| 2 | Eli Lilly | 983.57 Bn | 978.29 Bn | 16.22 Bn | 1.39 |
| 3 | Johnson & Johnson | 553.56 Bn | 531.50 Bn | 15.96 Bn | 0.68 |
| 4 | AbbVie | 383.35 Bn | 374.00 Bn | 10.78 Bn | -9.70 |
| 5 | Merck | 281.71 Bn | 276.06 Bn | 12.09 Bn | 1.07 |
| 6 | Amgen | 182.20 Bn | 170.16 Bn | 5.87 Bn | 6.24 |
| 7 | Gilead Sciences | 153.71 Bn | 145.98 Bn | 5.52 Bn | 0.94 |
| 8 | Pfizer | 143.75 Bn | 130.98 Bn | -1.21 Bn | 0.72 |
| 9 | Bristol Myers Squibb | 109.71 Bn | 99.25 Bn | 8.07 Bn | 2.22 |
| 10 | Medicus Pharma | - | - | - | -78.03 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -78.03 |
| Sep 30, 2025 | -7.49 |
| Jun 30, 2025 | 1.45 |